Finance, Grants, Deals

VectorY raises funds for neurodegenerative disease pipeline

Country
Netherlands

Netherlands-based VectorY Therapeutics BV has raised €74.5 million to support development of new products for neurodegenerative diseases using a vector technology that enables the production of therapeutic antibodies in vivo. The financing includes new investors Angelini Ventures, Invest-NL of the Netherlands and the European Investment Bank. A group of returning investors including Forbion and Eli Lilly & Co also participated. 

Series A funding for protein degrader

Country
United Kingdom

A UK company with technology for potentially removing disease-associated proteins from the brain has raised $60 million in Series A financing from a syndicate led by 4BIO Capital and new investor Eli Lilly and Co. Oyster Therapeutics Ltd, formerly known as Kesmalea Therapeutics, has developed a new version of protein degradation, a natural process by which cells in the body breakdown proteins that are damaged or that are no longer needed in order to maintain equilibrium. As therapies, protein degraders are being used by multiple companies to clear defective proteins from cells.

Oxford spin-out raises £67 million

Country
United Kingdom

A spin-out from the University of Oxford, UK, has raised £67 million from a Series A financing to advance clinical development of a new monoclonal antibody for treating essential thrombocythaemia (ET), a rare blood cancer. Alethio Therapeutics Ltd is building a portfolio of medicines to treat myeloproliferative neoplasms of which ET is one. 

New deal between BI and China group

Country
Germany

Germany-based Boehringer Ingelheim GmbH has broadened a two-year oncology agreement with Sino Biopharmaceutical Ltd of Hong Kong, enabling the two parties to explore treatments based on antibody-drug conjugates (ADCs) and T cell engagers. The companies launched their first collaboration in 2024 when BI agreed to supply Sino, now known as the SBP Group, with a small group of experimental drugs for further development.

AM-Pharma is acquired

Country
United Kingdom

AM-Pharma BV of the Netherlands is being acquired by a specialist healthcare company in the UK in a deal that will see its enzyme replacement therapy for hypophosphatasia (HPP) advance to Phase 2. The buyer is Ambrose Healthcare Ltd which already has two rare disease programmes in its portfolio and is positioning itself for more. This comes at a time when the US Food and Drug Administration is updating its guidance for the developers of drugs for rare diseases. Current estimates put the number of these diseases at 7,000 to 10,000 globally.

Hansoh concludes new ADC deal with Roche

Country
China

Hansoh Pharmaceutical Group Co Ltd announced a second antibody-drug conjugate (ADC) deal with the Roche Group on 19 October, giving the Chinese company an upfront payment of $400 million. The two companies did not disclose the specific cancers that they will be investigating. They did however say that Hansoh will lead early development of the programmes up to the completion of global Phase 1a clinical trials. After this, Roche will be responsible for further development worldwide – excluding the Chinese mainland, Hong Kong, Macau and Taiwan.

OMass raises $310 million in Series C financing

Country
United Kingdom

OMass Therapeutics Ltd, a 2016 spin-out from the University of Oxford, has raised $310 million in a Series C financing to support development of its lead programme for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The funding was announced on 15 October.

AZ accelerates collaborations

Country
United Kingdom

AstraZeneca Plc is to explore the use of artificial intelligence in drug development and expand its oncology portfolio under two new collaborations with US companies. The first, announced on 28 September, is an equity investment and clinical collaboration with Summit Therapeutics Inc under which the companies will investigate combination therapies of a bispecific antibody from Summit with antibody-drug conjugates (ADCs) from AstraZeneca. 

Launch of siRNA delivery company

Country
United Kingdom

A new platform company focused on the delivery of small interfering RNA (siRNA) to cells was launched on 13 October with the goal of addressing one of the main limitations of genetic medicines – reaching tissues beyond the liver. Undecimal Bio Ltd is a spin-out of Eleven Therapeutics (UK) Ltd, a synthetic medicines company. It has raised $18 million in seed financing from a syndicate co-led by 4BIO Capital and IQ Capital of the UK. Its initial therapeutic focus is renovascular disease.

Scarlet cells engage DARPA

Country
United Kingdom

In the US and elsewhere, programmes financed by governments for national defense can take many forms – including to support basic science. The Defense Advanced Research Projects Agency (DARPA) of the US, originally founded in the late 1950s to develop satellite technology, has in recent years branched out into computers and vaccines. On 23 September, DARPA stepped deeper into biology with the award of a research grant of up to $14 million to a consortium led by Scarlet Therapeutics Ltd of the UK to develop engineered, laboratory-produced red blood cells for defense.